To compare renal functional changes after percutaneous cryoablation (PCA) or partial nephrectomy (PN).
Introduction
Partial nephrectomy (PN) is the standard of care for treating early stage RCC and can provide oncological control similar to that of radical nephrectomy (RN) [1] . However, more recently, renal mass ablation has emerged as an acceptable alternative to PN in select elderly patients and those with significant co-morbidities. When compared with PN, renal mass ablation has the potential advantage of reduced morbidity without the need for an extirpative surgery [2, 3] . In addition, the oncological outcomes of renal mass ablation are similar to PN, albeit with a potentially higher local recurrence rate [1, [4] [5] [6] .
With the achievement of excellent oncological outcomes with nephron-sparing strategies, focus has shifted towards minimising the morbidity and long-term sequelae of treatment. In particular, the preservation of renal function has become of paramount importance due to the wellrecognised effects of chronic kidney disease (CKD) on both morbidity and mortality [7, 8] . It is well established that PN results in a significantly greater preservation of renal function as compared with RN [9] [10] [11] [12] . However, the changes in renal function after renal mass ablation as compared with PN remains understudied and the results of previous studies are conflicting as to whether a difference between these modalities exists [13] [14] [15] [16] [17] . Therefore, in the present study, we investigated the difference in renal functional changes in patients undergoing percutaneous cryoablation (PCA) or PN in a large historical cohort.
Patients and Methods

Patient Selection
After Institutional Review Board approval, we identified adult patients treated with PCA or PN for a unilateral, solitary renal mass at the Mayo Clinic between 2003 and 2013. Our patient management and procedures for both PCA and PN were performed as previously described [4, 18, 19] . Patients with distant metastases, Stage 5 CKD, or who were receiving renal replacement therapy at the time of the procedure were excluded. There were 2 131 procedures identified for potential study inclusion amongst 2 082 distinct patients, including 481 PCA and 1 650 PN. In all, 45 of the 2 131 procedures under study were excluded because of missing data for one or more of the covariates.
Clinical Features and Outcomes Studied
Clinical features recorded included: age; sex; history of hypertension; history of diabetes mellitus; presence of a solitary kidney; tumour size; tumour side; and estimated GFR (eGFR) and CKD stage at baseline, at discharge, and at the 3-month follow-up. The primary outcomes of interest in this study were the absolute change and percentage change in eGFR from baseline to discharge and the 3-month followup, calculated as discharge value minus baseline value and 3-month follow-up value minus baseline value. In addition, the change in CKD stage from baseline to discharge and the 3-month follow-up were calculated. The 3-month follow-up eGFR was defined as the eGFR, calculated from a serum creatinine measurement, taken between 1 and 12 months that was closest to 3 months following the procedure. The eGFR was calculated using the Chronic Kidney Disease Epidemiology Collaboration formula and expressed as mL/ min/1.73 m 2 [20] . The CKD stages were defined according to the National Kidney Foundation Staging System: Stage 1, eGFR ≥90 mL/min/1.73 m 
Statistical Methods
Baseline features were summarised with means and standard deviations (SDs) or frequency counts and percentages. Comparisons of features between patients treated with PCA and PN were evaluated using the two-sample t-test, Wilcoxon rank-sum test, chi-squared, and Fisher's exact test.
To control for differences in baseline characteristics between PCA and PN patients, a propensity score (PS) for treatment was obtained using a logistic regression model with PCA vs PN as the outcome and the baseline features listed above as covariates. An additional 46 procedures were excluded because they had a PS that did not fall within the common range of the two treatment groups, leaving 2 040 procedures available for the PS analyses, including 448 PCA and 1 592 PN. PCA patients were matched 1:1 to PN patients using the calliper method based on the logit of the PS and a calliper width of 0.2-times the SD of the logit (0.30). Using this approach, 389 PCA patients were matched to 389 PN patients.
Additional PS techniques were used to incorporate all of the procedures in the cohort, including adjustment for PS quintiles and re-weighting using stabilised inverse probability weights (IPWs). Stabilised IPWs were truncated by setting weights below the first percentile to the value of the first percentile, and weights above the 99th percentile to the value of the 99th percentile. The mean stabilised IPW was 0.984 (SD 0.543), resulting in a pseudo cohort with a sample size of 2 008, including 410 PCA and 1 598 PN.
Associations between treatment group and the outcomes of interest were evaluated using linear and logistic regression models. Statistical analyses were performed using the Statistical Analysis System (SAS) version 9.4 (SAS Institute, Cary, NC, USA). All tests were two-sided, with P < 0.05 considered statistically significant.
Results
Amongst the entire cohort, before PS adjustments, patients undergoing PCA were older (mean 69 vs 59 years, P < 0.001), had smaller tumours (mean 3.1 vs 3.5 cm, P = 0.001) and had lower baseline eGFR (mean 63 vs 75 mL/min/1.73 m 2 , P < 0.001). They were also more likely to have a solitary kidney (14% vs 6%, P < 0.001) and a history of hypertension (77% vs 59%, P < 0.001) or diabetes mellitus (30% vs 18%, P < 0.001; Table 1 ). However, after PS adjustments these features were well balanced between the groups. Specifically, there were no statistically significant differences between the treatment groups after PS matching or after re-weighting by stabilised IPWs (Table 2 ). Among the 2 040 procedures included in the PS analyses, 1 820 (89%) had a discharge eGFR available for analysis, including 384 PCA and 1 436 PN. Additionally, there were 1 606 (79%) procedures with a follow-up eGFR available for analysis, including 339 PCA and 1 267 PN.
In the PS-matched analysis, the change in eGFR from baseline to discharge for PCA and PN patients was À3.1 and À1.1 mL/min/1.73 m 2 , respectively (P = 0.038), with a percentage change of À4.5% and 0% respectively (P = 0.006). From baseline to the 3-month follow-up, the absolute change in eGFR for PCA and PN patients was À4.3 and À2.1 mL/min/1.73 m change was À6.1% and À2.4% respectively (P = 0.005). Similar results were obtained after adjusting for PS quintiles and in the weighted IPW analysis. A comparison of renal functional outcomes between the treatment groups for the three PS techniques used is shown in Table 3 .
Among those with a follow-up eGFR available, 70/339 (21%) PCA patients and 228/1 267 (18%) PN patients had an increase in CKD stage from baseline to follow-up. The rate of CKD stage progression was similar between the treatment groups after PS matching (P = 0.12), after adjusting for PS quintiles (P = 0.15), and after re-weighting by stabilised IPWs (P = 0.099; Table 4 ). At follow-up, no patient in the PCA group and three patients in the PN group had developed endstage renal disease (ESRD, Stage 5 CKD).
Discussion
The preservation of renal function has become a major consideration when managing a patient diagnosed with a renal mass. Decreased renal function is associated with an increased risk of cardiovascular events, hospitalisation, and 
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Ischaemia time, min, mean (SD) PCA n = 0, PN n = 950 [7, 8] . In surgical patients, it is well established that RN has a significantly greater impact on renal function than PN [9] [10] [11] [12] and that RN patients are at a greater risk of developing CKD Stage ≥4 [11] . However, when comparing nephron-sparing approaches, such as renal mass ablation and PN, the differences in renal functional changes between treatment strategies, if any, are less well established. Thus, while ablative techniques can offer the potential advantages of shorter recovery and decreased complications, it previously remained unclear whether concerns about renal functional decline should influence treatment selection.
In the present study, we examined the effect of both PCA and PN on renal function in a large historical cohort, using PS techniques to adjust for clinical differences at baseline between the treatment groups. Regardless of treatment type, the average change in renal function from baseline after both procedures was slight at both discharge and follow-up. Although the absolute difference in eGFR changes between groups was small, it was statistically significant due to the large sample size, which allows for enough power to detect even small differences. However, the clinical significance of this difference is minimal and the effects on renal function of both of these modalities can probably be considered equivalent. Additionally, we found no difference in the risk of CKD stage progression between groups. Nonetheless, we identified that a significant proportion of patients undergoing both PCA and PN had CKD stage progression. Overall, our present results suggest that the preservation of renal function might not be a determining factor when choosing between treatments. However, patients undergoing both procedures require renal functional follow-up to identify and manage those with new onset CKD and those at risk for further declines in GFR.
Previous studies that have investigated the differential effect on renal function of ablation as compared to PN [13] [14] [15] [16] [17] have had mixed results. In a retrospective study by Larcher et al. [14] using the Surveillance, Epidemiology and End Results (SEER) database, patients undergoing PN had an increased risk of developing acute kidney injury within 30 days of surgery compared with patients undergoing renal mass ablation (9.4% vs 4.6%, P = 0.001) but the risk of longterm CKD stage progression or ESRD was similar between the groups. The major limitation of that study was that actual measurements of eGFR could not be compared. As we found in our present study, changes in renal function after both of these procedures are modest and using CKD stage progression or the development of ESRD as the primary outcome is unlikely to uncover whether actual differences exist between treatment modalities. In a study by Faddegon et al.
[15] comparing PN with radiofrequency ablation, which investigated changes in eGFR, there was no statistically significant difference in the risk of renal functional changes between groups. However, unlike the present study, the actual changes in eGFR were not reported making the clinical interpretation of their findings difficult.
Two small retrospective studies have also investigated the renal functional changes in patients with a solitary kidney undergoing renal mass ablation or PN. In a previous study from our institution by Mitchell et al. [13] , including 50 patients undergoing percutaneous ablation (PCA and radiofrequency ablation) and 62 patients undergoing PN, there was no difference in renal function outcomes between the two procedures at up to 3 months of follow-up. Given the small changes in renal function seen in both studies, the difference in results between that study and the present one probably reflects the greater statistical power of the present study to find a significant difference. Conversely, in a study by Raman et al. [16] , including 47 patients who underwent radiofrequency ablation and 42 who underwent PN, the decline in renal function after PN was significantly greater postoperatively and throughout follow-up. The study found a larger decline in renal function among patients undergoing PN than was seen in the previous study or in the present study, which may explain the difference in results. Although the advantage of studying this issue in patients with a solitary kidney is apparent, the present study is generalisable to a larger population of patients with renal masses.
We recognise that there are several limitations to the present study. First, the follow-up available is relatively short at only 3 months. However, several other authors have reported that the majority of renal functional decline after a surgical insult occurs early and that by 3 months the new baseline GFR is established [9] . Second, although we attempted to adjust for baseline patient and tumour characteristics using multiple statistical techniques, it is possible that there are confounders that were not adjusted for. Third, we did not compare oncological outcomes between the groups in the present study. However, the oncological outcomes of renal mass ablation compared with PN at our institution have previously been reported [4] . Fourth, our present results are only reflective of PCA and not necessarily radiofrequency ablation. We chose to focus our present analysis on PCA as this is the primary ablative modality currently used at our institution and radiofrequency ablation is generally reserved for small peripheral masses. Finally, all of these procedures were performed in a single high-volume centre, which could potentially limit the generalisability of the results. These limitations notwithstanding, we think our results support that renal functional changes after PN and PCA are roughly equivalent.
Conclusions
In the present study, we confirmed that renal functional changes after both PCA and PN are minimal, both in the perioperative period and at 3-months follow-up. While we observed a statistically greater decline in renal function when PCA was compared with PN, the clinical significance of this difference is minimal and the risk of CKD stage progression is similar between the two procedures. In patients who are candidates for either procedure, the effect on renal function should not be a major consideration when deciding between the two.
